Advice
Following a full submission
Iloprost trometamol nebuliser solution (Ventavis®) is accepted for restricted use within NHS Scotland for the treatment of patients with New York Heart Association Class III primary pulmonary hypertension as a second-line treatment where bosentan is ineffective or is not tolerated. It is an orphan product and efficacy data are very limited.
Iloprost should also be restricted to use only as an alternative in patients receiving other forms of prostacyclin treatment. It is not recommended for patients who would not otherwise have received prostacyclin treatment because it is not cost effective in this situation.
It is further restricted only to use by Specialists working in the Scottish Pulmonary Vascular Unit.
Download detailed advice68KB (PDF)
Medicine details
- Medicine name:
- Iloprost trometamol nebuliser solution (Ventavis®)
- SMC ID:
- 219/05
- Indication:
- Primary pulmonary hypertension
- Pharmaceutical company
- Schering Health Care Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 December 2005